Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Merck KGaA Considers Appealing CHMP Opinion On Erbitux Treatment For Non-Small Cell Lung Cancer
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC). Merck KGaA is evaluating potential appeal options requesting that the CHMP re-examine data demonstrating clinical relevant benefits to patients.
pharmacy online
Advances In Lab-Grown Motor Nerves Can Lead To Cures For Diabetic Neuropathy And Help Further Understand Multiple Sclerosis And Related Conditions
In the July issue of Biomaterials, published by Elsevier, researchers from the University of Central Florida (UCF) report on the first lab-grown motor nerves that are insulated and organized just like they are in the human body. The model system will drastically improve understanding of the causes of myelin-related conditions, such as diabetic neuropathy and later, possibly multiple sclerosis (MS). In addition, the model system will enable the discovery and testing of new drug therapies for these conditions.
News of the day
King Saud University Scientist Part Of Cancer Breakthrough
King Saud University professor, Dr. Adel Almogren, along with a diverse team of academic researchers from the United States, Canada, and Taiwan, has discovered a new process that could lead to a vaccine to block cancer cell adhesion and growth.
Nutrition

BioElectronics Announces Pivotal Clinical Study On Musculoskeletal Disorders

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced its sponsorship of a groundbreaking clinical study on musculoskeletal disorders. The randomized, double blinded and placebo-controlled study will be supervised by a primary investigator, Sheena Kong, MD of San Francisco, California in conjunction with several other leading physicians. "This is a very exciting field of research and we are looking forward to determining the safety and efficacy of BioElectronics Corporation"s ActiPatch for the treatment of many different types of musculoskeletal complaints," commented Dr. Kong. "Since my days studying at Harvard University I have been very interested in treatments such as Pulsed Electromagnetic Field therapy (PEMF) as an alternative to pharmaceuticals. We are currently in process of working with our Independent Review Board (IRB) and registering the study with the National Institutes of Health (NIH). Patient recruitment is expected to begin over the next few weeks. We believe this will be one of the largest studies ever completed on the subject of general muscular skeletal complaints." Andrew Whelan, CEO of BioElectronics Corp., added, "The sponsorship and completion of the study are significant events for our Company. While we are seeing success within the plastic surgery market and in our international distribution channels, we believe the U.S. markets for back, knee, foot/ankle, and elbow pain are our biggest opportunities. This study is specifically designed to allow us to apply to the U.S. Food and Drug Administration for an indication for pain relief for general muscular skeletal complaints. With the many concerns over the dangers of taking medications such as acetaminophen and NSAIDs, we believe U.S. consumers are looking for safer and more effective pain relief options. We believe our unique and patented drug-free technologies will effectively fill this need." The management team of BioElectronics will hold a conference call on Thursday, June 18 at 4:15 p.m. (EDT) to discuss this study and other ongoing clinical trials several of which are nearing conclusion. On the call Barry Eppley, M.D., D.M.D will discuss the recent clinical study on dysmenorrhea and Sheena Kong, MD will discuss the design of the musculoskeletal disorder study. To access the conference call, please dial 712-432-0080 approximately 10 minutes prior to the start time and enter access code 404367# to be placed into the conference. BioElectronics Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009